1. Introduction {#sec1}
===============

Sporadic inclusion body myositis (sIBM) is known as the most common acquired myopathy among people 50 years and older ([@bib2]). Given its similarities with Alzheimer\'s disease such as the late age of onset and the abnormal accumulation of proteins, the apolipoprotein E (*APOE*, OMIM\#107741) gene has been one of the most popular genes studied in sIBM ([@bib1]), but no association with sIBM disease risk was confirmed ([@bib4]). Recently, the "translocase of outer mitochondrial membrane 40" (*TOMM40*, OMIM\#608061) gene, which is adjacent to and in strong linkage disequilibrium with the *APOE* locus on chromosome 19, has been studied in 90 Caucasian patients with sIBM ([@bib3]). That study reported that among carriers of the *APOE* genotype ε3/ε3 or ε3/ε4, carriage of a very long (VL) polyT repeats in the intron 6 of *TOMM40* (rs10527454) was less frequent in sIBM compared with controls and was also associated with a later age of onset of sIBM symptoms ([@bib3]). To further investigate the previously reported association between *APOE*-*TOMM40* and sIBM, we genotyped *APOE* and the polyT repeat polymorphism in *TOMM40* in a large sIBM cohort of 158 affected cases from the International IBM Genetics Consortium and investigated their association with disease risk and the age of onset of sIBM.

2. Methods {#sec2}
==========

A total of 158 DNA samples from biopsy-confirmed sIBM patients (66.5% males) were collected from 9 centres around the world. The control group comprised 127 individuals with no history of neuromuscular disease. Restriction fragment length polymorphism was used for *APOE* genotyping. Fluorescence-based fragment size analysis was performed for genotyping the polyT repeat in intron 6 of the *TOMM40* gene (rs10527454). The polyT repeat alleles were classified based on the length of repeat (*N*) as originally established by [@bib5]. Genotypic frequencies for *APOE* and *TOMM40* polyT were compared between cases and controls using the chi-square or the Fisher\'s exact test. The associations between *APOE* genotypes, *TOMM40* polyT genotypes, ethnicity, gender, and age of onset of sIBM were analyzed by linear regression analyses. For all the analyses, *p* value \<0.05 was considered statistically significant (for details, see [Supplementary Data](#appsec1){ref-type="sec"}).

3. Results {#sec3}
==========

The *APOE* ε2/ε2 genotype was absent in both the sIBM cohort and the control group. No significant differences were found between patients and controls regarding *APOE* allelic and genotypic frequencies, considering neither only Caucasian patients nor the entire cohort. The distribution of *TOMM40* polyT repeat lengths was similar in the sIBM group (range 8--36 repeats) and controls (11--33 repeats) ([Supplementary Fig. 1](#appsec1){ref-type="sec"}). The frequency of neither *TOMM40* polyT repeat genotypes nor polyT alleles differed significantly between groups ([Supplementary Table 1](#appsec1){ref-type="sec"}). When the analysis was performed in the combined group of carriers of ε3/ε3 and ε3/ε4 *APOE* genotypes, there was still no association between of the presence of VL polyT repeats and sIBM risk ([Supplementary Table 2](#appsec1){ref-type="sec"}).

There was no significant association between different *APOE* alleles and the age of onset of sIBM. However, being a carrier of the polyT repeat, VL allele was significantly associated with a later age of onset by 3.7 years in average (95% confidence interval \[CI\] = 0.4, 6.9; adjusted *p* = 0.027). We repeated the analysis just for carriers of the *APOE* ε3/ε3 genotype. We found that *APOE* ε3-*TOMM40* VL allele carriers had an even later age of onset of sIBM by 4.9 years in average (95% CI = 1.1, 8.7; adjusted *p* = 0.013). Similar results were found when the analysis was restricted to Caucasians (by 4.0 years for a VL carriage, 95% CI = 0.4, 7.6; *p* = 0.028; by 5.4 years for carriage of a VL allele and *APOE* ε3/ε3 genotype, 95% CI = 1.2, 9.7; *p* = 0.013). Although not reaching statistical significance, there was also a trend for a later age of onset (by 2.7 years) in males compared with females ([Table 1](#tbl1){ref-type="table"}).

4. Discussion {#sec4}
=============

This is the largest cohort where the influence of the *APOE* and *TOMM40* genes in sIBM disease risk and features has been investigated. Concerning *APOE*, our findings confirmed that the *APOE* ε4 allele is not a susceptibility factor for developing sIBM, which is consistent with the previous studies ([@bib4]). *APOE* alleles were also not significantly associated with the age of onset of the disease. In addition, our findings did not replicate a previously reported association between *APOE*-*TOMM40* and risk of developing sIBM ([@bib3]). However, we observed that carriage of a VL repeat allele was significantly associated with a later age of onset of symptoms. This effect was even more pronounced among those also with the *APOE* ε3/ε3 genotype. This suggests that the *TOMM40* VL polyT repeat has a disease-modifying effect on sIBM by delaying the onset of symptoms, and the *APOE* ε3/ε3 genotype enhances this effect. Although the association between *APOE* and *TOMM40* and sIBM risk was not confirmed in our study, the finding of an association between the *TOMM40* VL polyT repeat and a later age of onset of sIBM may justify further gene expression studies in the future. In addition, there might be other variants within the *APOE*-*TOMM40* locus involved in the susceptibility to sIBM. Furthermore, identification of new genes and variants is crucial to improve our understanding of this complex disease.
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###### 

Influences of *APOE* alleles, *TOMM40* polyT repeat of VL length, ethnicity, and gender on the age of onset of sIBM using standard adjusted linear regression analysis

  Variable                                   Count   Age of onset (mean ± SD), y   Adjusted analysis[a](#tbl1fna){ref-type="table-fn"}   
  ------------------------------------------ ------- ----------------------------- ----------------------------------------------------- -----------
  Ethnicity                                                                                                                              
   Non-Caucasian                             16      56.7 ± 5.7                    Reference                                             
   Caucasian                                 141     60.0 ± 10.0                   2.8 (−2.3, 7.9)                                       0.28
  Gender                                                                                                                                 
   F                                         52      57.9 ± 10.4                   Reference                                             
   M                                         105     60.6 ± 9.3                    2.7 (−0.5, 5.9)                                       0.095
  *APOE*                                                                                                                                 
   ε2/ε4[c](#tbl1fnc){ref-type="table-fn"}   6       56.8 ± 5.8                                                                          
   ε3/ε3                                     99      60.2 ± 9.8                    Reference                                             
   ε2/ε3                                     19      56.9 ± 10.0                   −2.9 (−7.7, 1.9)                                      0.23
   ε3/ε4 and ε4/ε4                           33      60.4 ± 9.7                    1.6 (−2.4, 5.7)                                       0.43
  *TOMM40* polyT                                                                                                                         
   No VL carriage                            74      58.1 ± 9.7                    Reference                                             
   VL carriage                               83      61.2 ± 9.6                    3.7 (0.4, 6.9)                                        **0.027**
  *APOE-TOMM40*                                                                                                                          
   ε3/ε3 and polyT non-VL carriage           38      57.3 ± 9.9                    Reference                                             
   ε3/ε3 and polyT VL carriage               61      62.0 ± 9.4                    4.9 (1.1, 8.7)                                        **0.013**

Key: *APOE*, apolipoprotein E; CI, confidence interval; F, female; M, male; SD, standard deviation, sIBM, sporadic inclusion body myositis; *TOMM40*, translocase of outer mitochondrial membrane 40; VL, very long.

Each analysis was adjusted for gender, ethnicity, tissue, and genetic factors, except for the variable under study.

*p* value \< 0.05 was considered statistically significant (marked in bold).

ε2/ε4 was not included in the regression analysis for *APOE* alleles and the age of onset.
